Trial Profile
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 21 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2014 New trial record